Clinical Trial

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Study acronym: POLARIS-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-16; most recent amendment 2025-05-29.
Status change: Not Yet Recruiting → Recruiting 2024-07-30
Trial Details
NCT Number NCT06423911
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Enrollment 285 participants
Start Date 2024-02-05
Primary Completion 2025-12 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-06-03